Adaptimmune Therapeutics PLC
ADAP0.283USD
-0.002-1.01%
收盘 06/06, 16:00（美东）报价延迟15分钟
437.83M总市值
亏损市盈率 TTM
关于 Adaptimmune Therapeutics PLC 公司
Adaptimmune Therapeutics PLC 是一家临床阶段的生物制药公司。该公司专注于为癌症患者提供细胞疗法。其工程化 T 细胞受体 (TCR) 平台能够对 T 细胞进行工程化，以靶向和摧毁多种实体肿瘤类型的癌症。其细胞疗法候选药物包括 TCR T 细胞和 TruC T 细胞。其产品候选药物包括 afamitresgene autoleucel (afami-cel) 和 Lete-cel。afamicel 是一种细胞疗法，可为滑膜肉瘤患者提供治疗选择。该公司正在过渡 lete-cel，该疗法针对滑膜肉瘤和粘液样圆细胞脂肪肉瘤 (MRCLS) 患者的 NY-ESO 抗原。其临床管线包括 ADP-A2M4CD8 的 SURPASS-III II 期试验和 ADP-A2M4CD8 的 SURPASS I 期试验。该公司最先进的临床前项目是针对 PRAME 靶点 (ADP-600) 和 CD70 (ADP-520) 的 T 细胞疗法。ADAP-600 是一种工程化的 TCR T 细胞。
公司简介
公司代码ADAP
公司名称Adaptimmune Therapeutics PLC
上市日期May 06, 2015
成立日期2014
CEOMr. Adrian Rawcliffe
员工数量506
证券类型Depository Receipt
年结日May 06
公司地址60 Jubilee Avenue
城市ABINGDON
上市交易所NASDAQ Capital Market Consolidated
国家United Kingdom
邮编OX14 4RX
电话441235430000
网址https://www.adaptimmune.com/
公司代码ADAP
上市日期May 06, 2015
成立日期2014
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. John Lunger
Mr. John Lunger
Chief Patient Supply Officer
Chief Patient Supply Officer
170.89K
+53.91%
Dr. Elliot Norry, M.D.
Dr. Elliot Norry, M.D.
Chief Medical Officer
Chief Medical Officer
133.26K
+99.32%
Ms. Cintia Piccina
Ms. Cintia Piccina
Chief Commercial Officer
Chief Commercial Officer
111.07K
+559.70%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Joanna Brewer, Ph.D.
Dr. Joanna Brewer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. John Lunger
Mr. John Lunger
Chief Patient Supply Officer
Chief Patient Supply Officer
170.89K
+53.91%
Dr. Elliot Norry, M.D.
Dr. Elliot Norry, M.D.
Chief Medical Officer
Chief Medical Officer
133.26K
+99.32%
Ms. Cintia Piccina
Ms. Cintia Piccina
Chief Commercial Officer
Chief Commercial Officer
111.07K
+559.70%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月21日 周三
更新时间: 5月21日 周三
持股股东
股东类型
持股股东
股东统计
占比
EcoR1 Capital, LLC
10.34%
Long Focus Capital Management LLC
8.96%
Two Seas Capital LP
7.75%
New Enterprise Associates (NEA)
6.44%
MPM Capital Inc.
2.01%
Other
64.50%
持股股东
股东统计
占比
EcoR1 Capital, LLC
10.34%
Long Focus Capital Management LLC
8.96%
Two Seas Capital LP
7.75%
New Enterprise Associates (NEA)
6.44%
MPM Capital Inc.
2.01%
Other
64.50%
股东类型
股东统计
占比
Hedge Fund
18.51%
Investment Advisor/Hedge Fund
16.38%
Venture Capital
6.44%
Research Firm
1.46%
Investment Advisor
1.40%
Individual Investor
0.63%
Pension Fund
0.07%
Other
55.11%
机构持股
更新时间: 2月22日 周六
更新时间: 2月22日 周六
报告期
机构数
持股数
持股占比
持股变动
2025Q1
190
114.17M
43.26%
-32.76M
2024Q4
195
128.66M
50.28%
-22.55M
2024Q3
199
155.41M
60.76%
-9.79M
2024Q2
202
157.35M
61.56%
-15.41M
2024Q1
213
165.17M
64.85%
-7.14M
2023Q4
210
146.11M
64.44%
-17.89M
2023Q3
229
151.45M
66.86%
-8.97M
2023Q2
226
147.93M
65.80%
+13.35M
2023Q1
200
118.51M
71.56%
-15.30M
2022Q4
207
116.34M
70.73%
-22.36M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
EcoR1 Capital, LLC
27.40M
10.65%
--
--
Dec 31, 2024
Long Focus Capital Management LLC
20.49M
7.97%
+7.19M
+54.09%
Dec 31, 2024
Two Seas Capital LP
14.84M
5.77%
+14.84M
--
Dec 31, 2024
New Enterprise Associates (NEA)
17.08M
6.64%
--
--
Dec 31, 2024
MPM Capital Inc.
5.56M
2.16%
--
--
Dec 31, 2024
MPM BioImpact LLC
5.10M
1.98%
--
--
Dec 31, 2024
Morgan Stanley & Co. LLC
1.01M
0.39%
-265.02K
-20.74%
Dec 31, 2024
Rock Springs Capital Management LP
2.48M
0.97%
+58.00K
+2.39%
Dec 31, 2024
Acadian Asset Management LLC
510.22K
0.2%
+510.22K
--
Dec 31, 2024
Renaissance Technologies LLC
2.53M
0.98%
+869.95K
+52.51%
Dec 31, 2024
查看更多
持股ETF
更新时间: 6月6日 周五
更新时间: 6月6日 周五
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.33%
SPDR S&P International Small Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Simplify Propel Opportunities ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Biotechnology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Invesco NASDAQ Future Gen 200 ETF
占比0.33%
SPDR S&P International Small Cap ETF
占比0.01%
Fidelity Enhanced Small Cap ETF
占比0%
ActivePassive International Equity ETF
占比0%
SPDR Portfolio Developed World ex-US ETF
占比0%
Simplify Propel Opportunities ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
iShares Biotechnology ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
